GLG News by Multiple Myeloma Physicians

Revlimid has significant activity in non Hodgkin's lymphomas (NHL)as well as chronic lymphatic leukemia (CLL) although why is somewhat unclear.

The design and application of molecularly targeted agents should be based on their efficacy / toxicity ratio

Avastin, an antiangiogenic agent used in cancer and other disorders, may have more side effects than originally recognized including proteinuria as well as kidney damage.

The identification of novel molecular targets the targeting of which might generate satisfactory anti-cancer results is by no means optimistic.

Pharma recommends more drug than may actually be needed. This does not apply just to Cerezyme, but the Epo products (Amgen & J&J), Avastin (Genentech.)

FDA panel recommended these new instructions after the failure and the over-estimated design of previous conducted clinical trials

Prison terms to be handed out for fraud by a health care financing firm. Go figure?

This is an agent, approved for use with restrictions, in ITP.

Epo products (Aranesp, Procrit, Epogen) from Amgen and J & J will be restricted to some degree with control of hemoglobin levels, NO use in curable malignancies ..." the panel voted 11 to 2 in recommending that the drugs not be used in cancer patients who are likely to be cured from their...

FDA panel recommned approval of Amgen's Nplate for patients with refractory/recurrent chronic ITP who have failed other therapies like steroids, immunoglobulins, Rituximab and spleenectomy. The safety/efficacy profile was favorable for this relatively narrow indication, although long term safet issues...